What are we talking about?
Priapism is an erection that lasts or persists with no connection to sexual stimulation and does not go away on its own (EAU, 2025). In practice, the 4-hour threshold is used: beyond it, the situation becomes urgent when the erection is painful. It is neither arousal nor a sign of “virility”: it is a blockage of blood circulation in the penis. Blood goes in, but it no longer comes out.
The condition is rare, but not exceptional: the European rare disease portal Orphanet classifies low-flow priapism (ORPHA:140949) with a prevalence of 1 to 9 per 100,000 people (Orphanet, 2026), the French Urology College guidelines give an incidence of 1.5 per 100,000 people (AFU, French Urology College guidelines), and a US study of emergency department visits (2006-2009) finds 5.34 cases per 100,000 men per year (Roghmann et al., 2013). The figures cannot be compared (different populations and methods), with two age peaks described between 7 and 10 years (sickle cell disease) and between 20 and 50 years (drug-related causes) (StatPearls, 2025); no national French measurement was found.
The three forms of priapism
- Ischemic priapism (“low-flow”, or veno-occlusive): the blood stagnates and becomes depleted of oxygen. This is the most common form, more than 95% of cases (EAU, 2025). The penis is fully hard and painful, while the glans stays soft. It is an emergency, comparable to a compartment syndrome: treatment must begin within 4 to 6 hours (EAU, 2025).
- Non-ischemic priapism (“high-flow”, or arterial): about 5% of cases (EAU, 2025). It often follows a blow or an injury to the perineum, which creates a fistula between an artery and the corpora cavernosa; it can appear 2 to 3 weeks after the injury. The erection is painless, partial, sometimes fluctuating, and resolves spontaneously in 62% of cases (StatPearls, 2025). It is not an emergency in the strict sense, but you should see a doctor (EAU, 2025) (AFU, French Urology College guidelines).
- Intermittent priapism (“stuttering”): painful erections that come back in episodes, often during sleep. It is common in boys and men with sickle cell disease (42 to 64%) (EAU, 2025). Any episode that goes on for long is treated like ischemic priapism. It differs from sleep-related painful erections during REM sleep (15 to 60 minutes, without ischemia or blood disorder) (StatPearls, 2025).
Causes
- Sickle cell disease and other blood disorders (thalassemia, clotting disorders, leukemia): the leading cause in children (63%) and the cause of 23% of cases in adults (EAU, 2025). About a third of adult men with sickle cell disease are affected, often from before puberty (Idris et al., 2022).
- Injections into the penis (alprostadil, papaverine…): the risk ranges from 0.4 to 35% depending on the product, and is under 1% for prostaglandin E1 (EAU, 2025). The official leaflet requires contacting a doctor or the emergency department if the erection lasts 4 hours or more (ANSM, 2014).
- Certain medicines: in published cases of drug-induced priapism, second-generation antipsychotics account for 33.8%, alpha-blockers 8.8%, and oral erection medicines (PDE5 inhibitors) only 2.9% (Rezaee et Gross, 2020). Trazodone, an antidepressant sometimes used as a sleeping aid, is reported twice as often as PDE5 inhibitors in the US pharmacovigilance database (Rezaee et Gross, 2020). One review estimates that nearly half of drug-induced priapism is attributed to antipsychotics (Hwang et al., 2021). Anticoagulants and certain antidepressants or blood pressure medicines are also on the British health service list (NHS, 2023).
- Drugs (cocaine, cannabis) (NHS, 2023): cocaine users seek care on average after more than 40 hours and need more procedures; the outlook is more guarded (Actas Urol Esp, 2024).
- An injury to the perineum or penis, or a spinal cord injury (EAU, 2025), and more rarely a cancer invading the area (bladder, prostate) (EAU, 2025).
- No cause found in 30 to 50% of cases according to the French guidelines (AFU, French Urology College guidelines).
Testosterone at a physiological dose does not cause priapism (EAU, 2025). In children, sickle cell disease is the main cause, far ahead of leukemia and injuries (EAU, 2025).
Time decides everything
Damage to the smooth muscle of the corpora cavernosa builds up with the duration of ischemia. The benchmarks from the guidelines:
- From 1 hour for a person with sickle cell disease who has a painful erection (British health service) (NHS, 2023).
- 3 to 4 hours: go to the emergency department (NHS, 2023); 4 hours in the official alprostadil leaflet (ANSM, 2014) and in the European guidelines (EAU, 2025).
- 4 to 6 hours: recommended start of treatment; beyond 6 hours, the French guidelines describe a risk of progressive damage to the smooth muscle fibers (AFU, French Urology College guidelines). From 14 hours, smooth muscle cells begin transforming into fibroblasts, and at 24 hours cellular necrosis sets in (StatPearls, 2025).
- After 20 to 24 hours, the risk of erectile dysfunction rises markedly (from 30 to 70% at follow-up depending on duration, and up to 90% without normal intercourse after 24 hours) (EAU, 2025) (StatPearls, 2025) (Capogrosso et al., 2024); in a series of 186 cases, it is multiplied by 25 after 20 hours and by 61 after 36 hours (Borrell et al., 2026). Beyond 36 hours, US guidelines state that the likelihood of recovering erectile function is low (AUA/SMSNA, 2021).
- Around 48 hours, damage to the smooth muscle spreads; an intervention after 48 to 72 hours relieves the pain but does little to protect the erection (EAU, 2025).
Conversely, when the shunt is done within 24 hours, 78 to 100% of men regain spontaneous erections (EAU, 2025).
That window is not a guarantee. In a London series of 45 men who had a T-shunt with tunneling of the corpora cavernosa after first-line treatment failed, the priapism was relieved in every man whose episode had lasted less than 24 hours but in only 30% of those whose episode had lasted more than 48 hours; six months later the erectile function score (IIEF-5) had fallen on average from 24 to 7.7, erectile dysfunction was still present, according to the authors, in 50% of patients when the priapism had lasted less than 24 hours, and every man operated on after 48 hours had necrotic smooth muscle on biopsy and needed a penile prosthesis (Zacharakis et al., 2014). In an older Egyptian series, 15 of the 35 men reviewed on average 66 months after the episode (43%) had kept their erections; priapism lasting more than 48 hours and the lack of complete detumescence after treatment were the factors most closely linked to erectile dysfunction (El-Bahnasawy et al., 2002).
The 4 to 6 hour mark is a precaution rather than a threshold measured in men: a 2022 review notes that it rests on few animal studies and on a cavernous blood pH measured at an average of 6.9 after 4 to 6 hours, that in animals the smooth muscle still looks normal under the microscope after 6 to 8 hours of erection, and that several retrospective clinical series report preserved erections in many men whose priapism was relieved within 6 to 12 hours; data on erectile outcome are scarce for delays under 6 hours (Dekalo et al., 2022). This does not change what to do: seeking care from 4 hours on remains what the guidelines ask.
What to do right away
- Do not wait for it to pass. A painful erection that lasts does not reliably resolve on its own.
- Call emergency services (15 or 112 in France) or go to the emergency department if the erection goes beyond 4 hours (3 to 4 hours for the British health service), and from 1 hour in case of sickle cell disease (NHS, 2023). Do not drive yourself; get someone to go with you and bring your medicines (NHS, 2023).
- Say right at reception when it started, any sickle cell disease, any injection into the penis, your medicines (antipsychotics, antidepressants, anticoagulants) and any substances used: the care team uses this to choose the procedure (EAU, 2025).
- While waiting, the British health service suggests trying to urinate, taking a hot bath or shower, drinking plenty of water and walking, and advises against cold packs, sex, masturbation, alcohol and tobacco (NHS, 2023). Cold is cited among the “small measures” in the French guidelines (AFU, French Urology College guidelines), but the European and US guidelines consider these measures rarely effective (1 to 55% resolution in the European review, 75% failure of oral tablets) and note that cold can worsen a sickle cell crisis (EAU, 2025) (StatPearls, 2025) (Capogrosso et al., 2024): none of them should delay leaving for care.
- After an injection into the penis: do not inject again and do not take another erection medicine; the official leaflet advises against combinations (ANSM, 2014).
What happens in hospital
For ischemic priapism, treatment proceeds in stages (EAU, 2025):
- Assessment: examination, blood test (blood count, clotting, sometimes hemoglobin electrophoresis), Doppler ultrasound, and analysis of blood drawn from the corpora cavernosa: blood that is low in oxygen and acidic (pO2 below 30 mmHg, pH below 7.25) indicates ischemia (EAU, 2025).
- Needle aspiration with a fine needle, under local anesthesia, until red blood comes back; a saline flush is possible (aspiration alone resolves about 33% of cases, and up to 66% with saline irrigation) (EAU, 2025) (StatPearls, 2025) (AFU, French Urology College guidelines).
- Injection of a medicine that narrows the blood vessels (diluted phenylephrine at 100 to 500 µg/ml, for instance 200 µg every 3 to 5 minutes up to 1 mg in one hour; etilefrine or ephedrine in France) into the penis, repeated if needed, with blood pressure monitoring (EAU, 2025) (AUA/SMSNA, 2021) (AFU, French Urology College guidelines). Combined with aspiration and irrigation, it resolves 70 to 100% of episodes (81 to 86% within the first 24 to 36 hours versus 58% alone) and reduces the need for a surgical shunt to 15 to 28% (versus 43 to 63% without aspiration) (AUA/SMSNA, 2021) (StatPearls, 2025) (Capogrosso et al., 2024).
- Distal surgical shunt if these measures fail: a connection is created at the tip of the penis between the corpora cavernosa and the glans or corpus spongiosum (with or without tunneling) to let the blood out; proximal shunts are now abandoned or discouraged due to lack of proven benefit and higher complication rates (EAU, 2025) (Milenkovic et al., 2024) (AUA/SMSNA, 2021). In France, the AFU describes the operation (anesthesia, puncture through the glans, incision, urinary catheter possible for 24 hours) and its risks: hematoma, recurrence, erectile dysfunction or even permanent loss of erections, altered sensation of the glans (AFU, 2012).
- Penile prosthesis in late cases (more than 36 to 48 hours) or refractory ones: early placement, within the first three weeks (EAU, 2025) (AUA/SMSNA, 2021); a meta-analysis found that placement within 30 days reduces complications and fibrosis and improves satisfaction (Sex Med Rev, 2024). In a London comparison of 95 men, a prosthesis placed a median of 7 days after the onset of priapism (68 men) gave 96% satisfaction and ability to have intercourse after a median follow-up of 17 months; placed a median of 5 months after (27 men), it required a second opening of the corpora cavernosa and smaller cylinders in 80% of cases because of dense fibrosis, and satisfaction was only 60%, mainly because of penile shortening (Zacharakis et al., 2014).
For non-ischemic priapism, treatment starts with observation, perineal compression or ice, then embolization (closing the leaking artery, with 85.7 to 100% success and 75 to 100% preserved erectile function) is offered if the situation persists; surgery is the last resort (Carnicelli et Akakpo, 2018) (Milenkovic et al., 2024) (EAU, 2025). In a person with sickle cell disease, the urologist treats the erection without delaying the procedure, while the hematologist manages hydration, pain and oxygen (exchange transfusion is not the primary treatment for an acute episode) (AUA/SMSNA, 2022).
Preventing a recurrence
- Sickle cell disease: prevention is discussed with the hematologist and the reference center; French protocols provide for an emergency pathway agreed in advance (HAS, 2010). The options cited (hormonal treatment, low-dose PDE5 inhibitor taken in the morning with a soft penis, hydroxyurea, etilefrine, pseudoephedrine, digoxin, gabapentin, home self-injection of a vasoconstrictor medicine) rest on limited evidence: the Cochrane review finds only three trials and 102 participants, with low to very low certainty (Cochrane, 2020). In a cohort of 24 evaluable patients on scheduled daily PDE5 inhibitors, emergency department visits dropped 4.4-fold and 92% of patients reported improvement (Hou et Burnett, 2021). Hormonal treatment (ketoconazole, cyproterone acetate, GnRH agonists) is not offered before sexual maturity and the AUA strongly recommends informing patients that it may impair fertility and sexual function (AUA/SMSNA, 2022) (EAU, 2025).
- Injections into the penis: lowest effective dose, never combined with another erection medicine, and a known warning threshold (ANSM, 2014).
- Medicines that carry a risk: if you take an antipsychotic, know that priapism is possible; the best clue is a history of prolonged, painless erections (Hwang et al., 2021).
Afterwards: erection, sexuality and the couple
Prolonged low-flow priapism sometimes leaves erectile dysfunction and fibrosis of the corpora cavernosa (AFU, French Urology College guidelines). After a shunt, a follow-up visit takes place a few weeks later (AFU, 2012), and sex is not allowed for 4 to 6 weeks according to the sheet updated in 2025 (AFU, 2025). If the erection does not return, the prosthesis can restore a sex life with penetration (Sex Med Rev, 2024).
The impact is not only physical. In men with sickle cell disease, priapism is associated with shame and embarrassment, which delay speaking up and seeking care, and affects psychological, sexual and physical well-being (J Pediatr Hematol Oncol, 2022). In children, untreated ischemic priapism can leave erectile and psychosexual problems in adulthood (EAU, 2025). In the couple, fear of another episode at night, avoidance of intimacy or fear of impotence are things to talk about, with a doctor, a psychologist or a sex therapist. For ordinary erectile dysfunction and its treatments, see erectile dysfunction and erection medicines.
Common myths
- “It’s a sign of virility, it will pass.” No: when it is painful and lasting, it is an emergency (EAU, 2025).
- “It’s Viagra’s fault.” Oral erection medicines account for only 2.9% of published drug-induced cases; antipsychotics and trazodone are more often involved (Rezaee et Gross, 2020).
- “An ice cube will fix it.” The evidence is limited, the British health service advises against cold and it can worsen a sickle cell crisis (EAU, 2025) (NHS, 2023).
- “We’ll see tomorrow morning.” The risk of erectile dysfunction rises markedly from 20 hours (Borrell et al., 2026).
- “After priapism, you’re impotent.” Not necessarily: after a shunt done within 24 hours, 78 to 100% of men regain spontaneous erections.
- “It only happens to older men.” False: in boys with sickle cell disease, it often starts before puberty (Idris et al., 2022).
When to seek care, and who to see
Any painful erection lasting more than 4 hours (1 hour in case of sickle cell disease) is an emergency: call emergency services (15 or 112 in France), or go to the nearest emergency department. For short episodes that keep coming back, or to talk about an erection that has become difficult after priapism, the family doctor, the urologist or the sex therapist are the right people: see Who to see, and when. This text is for information; it does not replace a doctor’s advice.
State of the research
The guidelines rely mainly on case series and observational studies: randomized trials are rare. For prevention in people with sickle cell disease, the 2020 Cochrane review finds only three small trials (stilbestrol, sildenafil, ephedrine or etilefrine) and concludes that evidence is lacking (Cochrane, 2020). Two phase 2 trials that were under way in 2022 have since reported results (Idris et al., 2022): in the randomized PIN trial (64 men with sickle cell disease followed for 10 months), moderate-dose hydroxyurea reduced monthly priapism frequency by 58.3% and hydroxyurea plus tadalafil by 66.3% compared with baseline, with no significant difference between the two arms and a decrease in sperm count and motility that reversed within 3 months of stopping; in the SPARTAN trial (36 patients), crizanlizumab reduced episodes by 46% at 26 weeks without reaching statistical significance (and its European marketing authorization was withdrawn in 2023) (Idris et al., 2025). The most recent international guidelines (2024, published in 2026) and European systematic reviews confirm the overall logic: assess urgently, treat ischemia quickly with aspiration and phenylephrine, abandon proximal shunts, do not rush a procedure for high-flow priapism, consider a prosthesis early after a failure (AUA/SMSNA, 2022) (Milenkovic et al., 2024) (ICSM, 2026). Research stopped on 18 November 2026.
The figures on duration and after-effects come mostly from single-centre case series (El-Bahnasawy et al., 2002) (Zacharakis et al., 2014) (Zacharakis et al., 2014), and the 4 to 6 hour mark rests on few animal studies (Dekalo et al., 2022): they give orders of magnitude, not exact thresholds.
